News

Data show none of the treated volunteers to develop COVID-19 experienced a severe form of the disease, versus 11 given placebo.

The Vanderbilt Professor of Preventive Medicine shares thoughts on the first potential COVID-19 vaccine, at a time of record new daily cases.

The biotechnology has reached it COVID-19 case accrual mark, and announced plans to submit data to an independent review board.

Findings from Michigan show financial, mental health, and cardiopulmonary impacts are prevalent in patients 2 months after hospital care.

Blood pressure medication adherence should continue for patients with COVID-19, and atrial fibrillation and atrial flutter can worsen outcomes in hospitalized COVID-19 patients.

HIV care has made leaps and bounds over the past few years. New guidance for primary care physicians addresses these changes and acknowledges the diversity and complexity of individuals with HIV.

Findings highlight the importance of limiting “nondiscriminate broad-spectrum antibiotic exposures.”

Large cohort study quantifies risk for hospital admission for COVID-19 among healthcare workers and members of their households.

CDC and WHO Data shows a 50% increase worldwide from 3 years ago.

A study looking at these 2 populations in a hospital setting offers some positive news.

The authors also addressed how HIV may interact with the coronavirus.

The country halted the Sinovac investigational vaccine due to what was being reported as a serious adverse event.

Alzheimer’s disease, dementia, and genetic variations in areas key to viral infection are risk factors for severe COVID-19 a new study suggests.

Bamlanivimab should be administered as soon as possible after a positive test, and within 10 days of developing symptoms, Eli Lilly said.

When administered every two months, cabotegravir is 89% more effective than daily pills in preventing HIV acquisition in women.

The new research letter also highlights a concerning rate of infection among Latino patients.

The company is still awaiting its threshold for total COVID-19 infections in its 44,000-patient assessment. Nonetheless, they believe they have made history.

A new survey shows just 2% of children with rheumatic disease reported COVID-19 positive test results or symptoms through early May.

New findings show subsequent drops in incidence, hospitalizations, and mortalities once the state set stay-at-home orders, mask mandates, and contact tracing.

The final report of remdesivir trial supports its approved treatment for COVID-19 after preliminary findings enabled emergency use authorization.

A similar shutdown seems inevitable, but there may be an alternative.

The test simultaneously recognizes the S1 and S2 subunits of the virus' spike protein in one sample, providing better sensitivity.

Neurological symptoms of COVID-19 ranging from dizziness to microclots could be the result of destabilization of the blood-brain barrier caused by virus spike proteins circulating in the blood.

The country moves into a difficult phase of the pandemic as fall slides into winter with no national mandates and no vaccine.

In a survey, a panel of experts sees the American response as problematic and weighs in on universal masking.

Phase 2 trial demonstrates novel investigational antifungal Fosmanogepix is tolerated and efficacious in patients with renal Insufficiency.

Investigators found these populations are younger and are living at or below poverty were at lower adherence to ART.

Disagreement among health officials, politicians, and the media leads to inconsistent levels of compliance with guidelines.

LY-CoV555 was derived from a patient with COVID-19 and developed by Eli Lilly.